Elan Gorshein, DO, JD, MPH
DownloadHi-Res Photo
Cards
Appointments
Hematology
Primary
Contact Info
About
Titles
Assistant Professor of Medicine (Hematology)
Biography
Dr. Elan Gorshein cares for patients at the Smilow Cancer Hospital Care Center in Guilford and focuses his practice in the care of patients with hematological malignancies. Dr. Gorshein received his Doctor of Osteopathic Medicine degree from Rowan University – School of Osteopathic Medicine in New Jersey and graduated from Rutgers University School of Law, also in New Jersey with a Juris Doctor degree. He received his Master in Public Health from Johns Hopkins Bloomberg School of Public Health. During his fellowship training, Dr. Gorshein received the Melvyn H. Motolinsky Research Foundation Fellow Award. He focuses his practice in the care of patients with hematological and thoracic malignancies.
Appointments
Hematology
Assistant ProfessorPrimary
Other Departments & Organizations
Education & Training
- MPH
- Johns Hopkins Bloomberg School of Public Health (2017)
- DO
- Rowan University – School of Osteopathic Medicine, Osteopathic Medicine (2012)
- JD
- Rutgers University School of Law, Law (2012)
Research
Research at a Glance
Yale Co-Authors
Frequent collaborators of Elan Gorshein's published research.
Publications Timeline
A big-picture view of Elan Gorshein's research output by year.
Natalia Neparidze, MD
Noffar Bar, MD
Sabrina Browning, MD
Terri Parker, MD
Alexa Siddon, MD
Karl Insogna, MD, FACP
13Publications
23Citations
Publications
2023
Dietary Patterns Among Individuals with Plasma Cell Disorders Compared to the General US Population
Traore K, Taneja A, Gorshein E, Castro F, Derkach A, Martinez J, Serrano E, Lesokhin A, Ahlstrom J, Block T, Hydren J, Usmani S, Shah U. Dietary Patterns Among Individuals with Plasma Cell Disorders Compared to the General US Population. Blood 2023, 142: 7363. DOI: 10.1182/blood-2023-186913.Peer-Reviewed Original ResearchConceptsBody mass indexPlasma cell disordersHigher HEI scoresFood frequency questionnaireGeneral US populationHEI scoresDietary patternsTotal fruit consumptionMultiple myelomaUS populationDietary interventionDietary guidelinesFruit consumptionCell disordersHealthy dietBlock Food Frequency QuestionnaireElevated body mass indexLower body mass indexCancer-specific mortalityLong-term outcomesHealthy Eating IndexNutrition Examination SurveyHealthy dietary habitsRole of nutritionOlder age groups“Double‐hit” ineffective erythropoiesis—concurrent β‐thalassemia with α‐gene triplication and myelodysplastic syndrome with SF3B1 mutation
Chen P, Gorshein E, Tormey C, Siddon A, Perincheri S. “Double‐hit” ineffective erythropoiesis—concurrent β‐thalassemia with α‐gene triplication and myelodysplastic syndrome with SF3B1 mutation. American Journal Of Hematology 2023, 98: 984-988. PMID: 36688500, DOI: 10.1002/ajh.26856.Peer-Reviewed Original ResearchMeSH Keywords and Concepts
2021
Outcomes Among Primary Refractory Multiple Myeloma Patients in the Era of Monoclonal Antibodies: The Yale Experience
Liu Y, Kywe B, Crawford L, Lora F, Bar N, Browning S, Gorshein E, Parker T, Neparidze N. Outcomes Among Primary Refractory Multiple Myeloma Patients in the Era of Monoclonal Antibodies: The Yale Experience. Blood 2021, 138: 1635. DOI: 10.1182/blood-2021-146619.Peer-Reviewed Original ResearchCitationsConceptsAutologous stem cell transplantMedian overall survivalInternational Staging System stage IIRefractory multiple myeloma patientsOverall survivalMultiple myeloma patientsMultiple myelomaInduction therapyPartial responsePrimary refractoryInduction regimenMyeloma patientsMonoclonal antibodiesPlasma cellsInternational Myeloma Working Group criteriaYale New Haven Health SystemStage IIHigh-risk cytogeneticsGood partial responseRetrospective cohort studyMajority of patientsMRD-negative statusMonoclonal antibody therapyStem cell transplantImportant prognostic valueUse of Denosumab after Zoledronic Acid in Patients with Multiple Myeloma: Real-World Experience from 2015 to 2019 at Yale Cancer Center
Dosani T, Poteraj A, Parker T, Bar N, Browning S, Gorshein E, Anderson T, Insogna K, Neparidze N. Use of Denosumab after Zoledronic Acid in Patients with Multiple Myeloma: Real-World Experience from 2015 to 2019 at Yale Cancer Center. Blood 2021, 138: 4756. DOI: 10.1182/blood-2021-147466.Peer-Reviewed Original ResearchConceptsBone-modifying agentsUse of denosumabYale Cancer CenterZoledronic acidMultiple myelomaMM patientsCancer CenterMedian numberPhysician preferenceCommon reasonClinical practiceNew fracturesNuclear factor kappa-B ligandStudy periodApproval of denosumabEfficacy of denosumabIncidence of SREsMain treatment centreSmilow Cancer HospitalSuppress bone turnoverPatient's renal functionBone resorption markersCohort of patientsGlomerular filtration rateDate of diagnosis
2019
Impact of Insurance Status on Survival Outcomes in Adults with Acute Lymphoblastic Leukemia (ALL): A Single Center Experience
Krakora R, Shih W, Popli P, Gorshein E, Salaru G, David K, Bannerji R. Impact of Insurance Status on Survival Outcomes in Adults with Acute Lymphoblastic Leukemia (ALL): A Single Center Experience. Blood 2019, 134: 5071. DOI: 10.1182/blood-2019-129390.Peer-Reviewed Original ResearchConceptsProgression-free survivalAllogeneic stem cell transplantAcute lymphoblastic leukemiaTime of diagnosisAchievement of CRBetter overall survivalOverall survivalComplete remissionInsurance statusAcute myeloblastic leukemiaSurvival outcomesLymphoblastic leukemiaRegeneron PharmaceuticalsHealth insuranceSurvival rateSingle comprehensive cancer centerBetter progression-free survivalWorse progression-free survivalProportional hazards regression methodsPhiladelphia chromosome statusSingle-center experienceRetrospective chart reviewStem cell transplantComprehensive cancer centerLack of insurance
2017
Unusual Case of Esophageal Adenocarcinoma With Forearm Soft Tissue Metastasis
John E, Gorshein E, Dayan M, Katz K, Malhotra U. Unusual Case of Esophageal Adenocarcinoma With Forearm Soft Tissue Metastasis. The American Journal Of Gastroenterology 2017, 112: s901. DOI: 10.14309/00000434-201710001-01664.Peer-Reviewed Original Research
2016
Hip-related toxicity after prostate radiotherapy: Treatment related or coincidental?
Zelefsky M, Kollmeier M, Gorshein E, Pei X, Torres M, McBride S, Happersett L, Cohen G, Yamada Y. Hip-related toxicity after prostate radiotherapy: Treatment related or coincidental? Radiotherapy And Oncology 2016, 121: 109-112. PMID: 27756494, PMCID: PMC5546832, DOI: 10.1016/j.radonc.2016.08.010.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsDegenerative joint diseaseHip painPersistent hip painSevere hip painLocalized prostate cancerOnly variableProstate cancer patientsExternal beam radiotherapyHip revision surgerySalvage therapySevere painCancer patientsProstate cancerJoint diseaseLower incidenceBeam radiotherapyHip replacementConcurrent ADTMultivariate analysisPatientsRadiotherapyPainProstate radiotherapyIncidenceAmbulationA Difficult Position: Appendicitis in Platelet Refractory, Severely Neutropenic Patient
Ha K, Gorshein E, John E, Gharibo M. A Difficult Position: Appendicitis in Platelet Refractory, Severely Neutropenic Patient. The American Journal Of Gastroenterology 2016, 111: s667. DOI: 10.14309/00000434-201610001-01462.Peer-Reviewed Original Research
2015
The Case of Mistaken Identity: Entamoeba histolytica presenting as Community Acquired Pneumonia
Ha K, Gorshein E, Skole K. The Case of Mistaken Identity: Entamoeba histolytica presenting as Community Acquired Pneumonia. The American Journal Of Gastroenterology 2015, 110: s386. DOI: 10.14309/00000434-201510001-00894.Peer-Reviewed Original ResearchCitations
2014
Probiotic Enteric Regimen for Easing the Complications of Transplant
Gorshein E, Ambrosy S, Budney S, Vivas J, Manago J, McGrath M, Tyno A, Strair R. Probiotic Enteric Regimen for Easing the Complications of Transplant. Blood 2014, 124: 5877. DOI: 10.1182/blood.v124.21.5877.5877.Peer-Reviewed Original ResearchCitationsConceptsHematopoietic stem cell transplantAllogeneic hematopoietic stem cell transplantExtensive chronic GVHDChronic GVHDProbiotic Lactobacillus GGAcute GVHDStem cell transplantComplication of transplantRetrospective analysisCell transplantLactobacillus GGThree-month intervalsStage IIIStem cell transplant patientsPilot studyProphylaxis of GVHDPrimary end pointEvidence of diseaseRisk of GVHDCell transplant patientsMarrow Transplant RegistryEfficacy of probioticsAdministration of probioticsIntestinal GVHDHost disease
Clinical Trials
Current Trials
Phase 2 Study of Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory CD30 Positive T-cell Lymphoma
HIC ID2000029793RoleSub InvestigatorPrimary Completion Date02/01/2023Recruiting ParticipantsPhase 1b/2, Open-Label Study to Evaluate Safety and Tolerability of Epcoritamab in Combination With Anti-Neoplastic Agents in Subjects With Non-Hodgkin Lymphoma
HIC ID2000032539RoleSub InvestigatorPrimary Completion Date05/19/2029Recruiting ParticipantsA Phase II Evaluation of Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2-SN-38 Antibody-drug Conjugate, in Patients With Persistent or Recurrent Endometrial Carcinoma
HIC ID2000026850RoleSub InvestigatorPrimary Completion Date12/31/2024Recruiting ParticipantsParallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)
HIC ID2000032279RoleSub InvestigatorPrimary Completion Date12/31/2033Recruiting ParticipantsA Phase II/III Trial of Chemotherapy + Cetuximab vs Chemotherapy + Bevacizumab vs Atezolizumab + Bevacizumab Following Progression on Immune Checkpoint Inhibition in Recurrent/Metastatic Head and Neck Cancers
HIC ID2000032270RoleSub InvestigatorPrimary Completion Date12/15/2027Recruiting Participants
Clinical Care
Overview
Elan Gorshein, DO (doctor of osteopathic medicine), MPH, specializes in treating patients with hematologic malignancies at Smilow Cancer Hospital.
Hematologic malignancies are cancers that begin in blood-forming tissue, such as bone marrow and immune system cells, and include leukemia, lymphoma, and multiple myeloma. Osteopathic medicine focuses on treating the patient as a whole rather than addressing specific symptoms.
Dr. Gorshein has a JD (juris doctor) degree and is an assistant professor of clinical medicine (hematology) at Yale School of Medicine.
Clinical Specialties
Hematologic Oncology; Thoracic Oncology
Fact Sheets
Anemia
Learn More on Yale MedicineThrombocytopenia
Learn More on Yale MedicineChronic Myeloid Leukemia (CML)
Learn More on Yale MedicineMyeloproliferative Neoplasms
Learn More on Yale Medicine
Board Certifications
Medical Oncology
- Certification Organization
- AB of Internal Medicine
- Original Certification Date
- 2018
Hematology (Internal Medicine)
- Certification Organization
- AB of Internal Medicine
- Original Certification Date
- 2018
Internal Medicine
- Certification Organization
- AB of Internal Medicine
- Latest Certification Date
- 2018
- Original Certification Date
- 2015
Yale Medicine News
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileLinks & Media
News
- April 02, 2024
Yale Department of Internal Medicine Promotions and Appointments (April 2024)
- June 08, 2023Source: Cancer Network
The ‘Golden Age’ of Daratumumab: Highlights From an Expert Panel on Multiple Myeloma
- June 23, 2021
Smilow Cancer Hospital Care Center at Guilford physicians make ‘Top Docs’ list in Connecticut
- September 30, 2018
Smilow Cancer Hospital Care Center - Guilford
Get In Touch
Contacts
Appointment Number
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.